Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Benson DE et al. | 1994 | bacterium, <i>Pseudomonas aeruginosa</i> | DC, static magnetic field | 0.5 mT–0.2 T |
Gioia L et al. | 2013 | intact cell/cell culture, swine granulosa cells | static magnetic field | 2 mT |
Wocik-Piotrowicz K et al. | 2014 | intact cell/cell culture, U937 (human leukemic monocyte cell line) | magnetic field, static magnetic field, low frequency, 50/60 Hz, DC, co-exposure | 2–6.5 mT |
Laszlo J et al. | 2010 | bacterium, <i>Bacillus circulans, Escherichia coli, Micrococcus luteus, Pseudomonas fluorescens, Salmonella enteritidis, Serratia marcescens, Staphylococcus aureus</i> and yeast (<i>Saccharomyces cerevisiae</i>) | static magnetic field, DC | 2.8–476.7 mT |
Lin T et al. | 2014 | intact cell/cell culture, MDA-MB-468 cell line and T47D cell line (human breast carcinoma cells) | static magnetic field, DC | 3 mT |
Zafari J et al. | 2015 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line) and fibroblasts | static magnetic field, DC | 5–30 mT |
Tenuzzo B et al. | 2006 | intact cell/cell culture, human lymphocytes, mouse thymocytes, FRTL-5 cells (Fischer rat thyroid cells), Hep G2 cells (hepatic transformed cell line), HeLa cell line (human adenocarcinoma cell line), U937 (human leukemic monocyte cell line) and 3 DO cells (T cell hybridoma cell li | static magnetic field | 6 mT |
Tenuzzo B et al. | 2008 | intact cell/cell culture, U937 (human leukemic monocyte cell line) | static magnetic field | 6 mT |
Tenuzzo B et al. | 2009 | intact cell/cell culture, human lymphocytes | static magnetic field | 6 mT |
Stansell MJ et al. | 2001 | bacterium, <i>Escherichia coli</i> | static magnetic field | 8–60 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.